1. Introduction
===============

Among diverse acupuncture treatments in Korea, pharmacopuncture is a new and unique treatment method that combines acupuncture based on the meridian theory and herbal medicine based on Qi and flavor theory \[[@B001]\]. Meridian field pharmacopuncture (MFP) is a representative pharmacopuncture method. MFP is divided into aromatic and oil-based MFP. Oil-based pharmacopuncture is administrated to disorders caused by deficient body lubrication, and *Carthami-flos* (CF) pharmacopuncture, *Juglans sinensis dode* (JSD) pharmacopuncture, and *Cervi cornu parvum* (CC) pharmacopuncture are a few examples of oil-based pharmacopuncture \[[@B001]\]. CF is extracted from *Carthami-flos* (safflower) seed and is used to treat diseases with stasis or deficient body lubrication, such as vertebral disorders (neck pain), joints disorders, soft tissue damage, contusions, menstrual irregularity, deficient type constipation and muscle induration \[[@B001]-[@B004]\]. CC is a warm oil-based pharmacopuncture and is extracted from CC (deer antler). It greatly tonifies the original Yang (大補元陽), as well as Qi and blood (補氣血), replenishes essence and marrow (益精 髓), and strengthens sinew and bone (强筋骨). CC is used to treat sclerosis, various inflammatory disorders caused by the deficient body lubrication, tuberculosis, asthma, diabetes, hypotension, Yang Qi deficiency, and arthralgia \[[@B001], [@B005], [@B006]\]. *Carthami-flos* and *Cervi cornu parvum* pharmacopuncture (CFC) is a mixture of CF and CC and is applied to treat chronic diseases with static blood (瘀血) and dual deficiency of Qi and blood (氣血兩虛), such as degenerative spondyloarthropathy, degenerative musculoskeletal disorders, and so on \[[@B001]\]. Water-soluble *Carthami-flos* and *Cervi cornu parvum* pharmacopuncture (WCFC) is CFC emulsified in water and is developed to enhance the effect of CFC and to reduce the side effects caused by oil-based pharmacopuncture \[[@B007]-[@B009]\].

The safety of injecting herbal medicine into a muscle or a vein is very important. Water-soluble *Carthami-flos* (WCF) is the pharmacopuncture with CF emulsified in water. The method used to manufacture WCF is similar to that used to manufacture WCFC. On the bases of single intramuscular- dose toxicity tests \[[@B010]\] and single intravenous-dose toxicity tests, WCF was reported to be safe when injected into the body intramuscularly or intravenously \[[@B002]\]. Now, a toxicity study of WCFC is necessary. For that reason, we performed a single-dose intramuscular-injection toxicity study to evaluate the safety of WCFC and to estimate its approximate lethal dose.

2. Material and Methods
=======================

This study was approved by Institutional Animal Care and Use Committee of Biotoxtech Co. (Approval No: 130365). The tests were performed according to Good Laboratory Practice (GLP) regulation and toxicity test guidelines of the Ministry of Food and Drug Safety (MFDS).

To process the tissues of deer antlers (DA), we chopped 35 g of DA into small pieces and put them into 500 mL of 95% ethanol. The DA mixture was stirred 4 hours a day during cold storage for one week to extract all DA components; then, the stirred DA mixture was filtered with a Whatman™ nylon membrane filter (pore size: 0.45 μm), and 12 g of the filtered mixture was added to 1000 cc of safflower oil in a round flask. This was followed by decompressed concentration to volatilize ethanol completely. Ethanol vaporized at 55°C and was liquefied through the cooling tube; the DA components were dissolved into the safflower oil. The liquid ethanol was discarded, and the DA extract solution was transferred to the preparation tank. The transferred DA and safflower oil solution (CFC solution) was mixed by using nitrogen gas (N~2~, 99.99% purity) agitation for over an hour. The CFC solution was filtered with 0.2 μm pore filter paper (KA2DFLP02, Pall Corporation, U.S.A.) to remove endotoxin, and the filtered solution was added to water for injection (WFI) at an adequate rate in the reaction container. The CFC solution and an emulsifier were mixed with high speed agitator to make a WCFC solution. The pH of the WCFC solution was adjusted to pH 7.3 by using NaOH. The WCFC solution was passed through a filter (0.1 μm Sartorius) between the preparation and the filling tanks and was transferred to the filling tank by using N~2~ gas. The WCFC solution was subdivided, placed into vials, and sterilized at high pressure (high pressure sterilizer, fine FA, Korea) at 121°C for 30 minutes. The vials containing the WCFC solution were kept refrigerated at 4°C.

Five-week-old male (n = 24) and female (n = 24) Sprague-Dawley (SD) rats with weights ranging from 112.2 to 125.6 g in males and from 110.5 ─ 131.0 g in females were purchased from Orientbio Inc., Korea, for use in this study. When the animals were received, they underwent basic visual examinations, and their weights were measured by using an electronic scale (CP3202S, Sartorius, Germany). General symptoms were observed daily during the 7-day stabilization period. On the last day of the stabilization period, weights, general symptoms and weight changes were measured to confirm the normal conditions for all animals.

Animals were kept in stainless-steel wire cages with dimensions of 260 W × 350 D × 210 H (mm) under the following conditions: temperature in the range of 22.0 ─ 23.9°C, relative humidity in the range of 50.3% ─ 77.3%, a air change rate of 10 ─ 15 times/hour, a illumination time of 12 hours/day (7:00 am ─ 7:00 pm), and an intensity of illumination of 150 ─ 300 Lux. The breeding cage was changed once every two weeks. The breeding apparatuses were cleaned by using an automatic washer and were sterilized by using an autoclave. Solid feed (Teklad Certified Irradiated Global 18% Protein Rodent Diet 2918C, Harlan Laboratories, Inc., U.S.A.) was put into the feeding system for free intake. Drinking water was sterilized by using an ultraviolet water sterilizer.

All animals were put into grouped on the last day of stabilization (grouping day). Twenty male and twenty female rats whose weights were approximately equal to the mean weight were selected. Selected animals were randomized into 4 groups with 5 male rats and 5 female rats for each group (male weights: 179.8 ─ 197.0 g, female weights: 145.7 ─ 177.0 g) so that average weights per group were about the same. The remaining animals were excluded from the study.

An intramuscular injection route using a method applicable to Korean medicine clinics was selected because many kinds of pharmacopunctures have been injected into muscle or subcutaneous tissue to treat diseases at Korean medicine clinics. Dosages for the control and the high dose groups were 0.5 mL/animal of saline and of WCFC, respectively, and those for the middle dose group and the low dose group were 0.25 and 0.125 mL/animal, respectively. WCFC was injected into the muscle of the left femoral region by using a disposable syringe (1 mL, 26 gauge) (Table [1](#T001){ref-type="table"}).

In a pilot test, no deaths were observed for intramuscular injections of 0.5 mL/animal of WCFC into male and female rats (Biotoxtech Study No.: B13477P). Based on the pilot study and clinical experience, the injection doses selected for this study were 0.5 mL/animal for the high dose, 0.25 mL/animal for the middle dose, and 0.125 mL/animal for the low dose, the dose being reduced by a factor of 2 from group to group. Normal saline (Choongwae Pharma Corp., Korea) at a dose of 0.5 mL/animal was injected into the control group.

General clinical sign, such as types of toxicity, onset time, recovery time, etc., and deaths were observed 30 minutes, 1, 2, 4, and 6 hours after the first injection on the day of the first injection (day 0). General symptoms were observed daily for 14 days after injection. The body weights of the SD rats were measured on the day of the injection (before injection) and on the third, seventh, and fourteenth after the injection. Before necropsy, all animals were fasted for more than 18 hours. On the necropsy day (fifteenth day after injection), animals were anesthetized with isoflurane, and blood was taken from the abdominal aorta. Blood was kept in a 1-mL ethylenediaminetetraacetic acid (EDTA) tube, and hematologic tests were done by using a blood corpuscle analyzer (ADVIA 2120i, Siemens, Germany). The red blood cell count (RBC), hemoglobin concentration (HGB), hematocrits (HCT), mean corpuscular cell volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular cell hemoglobin concentration (MCHC), platelet count (PLT), white blood cell count (WBC), WBC differential counts (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), and reticulocyte (Reti) count were measured. For blood coagulation tests, blood was drawn in 2-mL tubes that contained 3.2% sodium citrate. The blood was centrifuged at 3,000 rpm for 10 minutes to collect the plasma. The prothrombin time (PT) and the active partial thromboplastin time (APTT) were measured with a coagulation time analyzer (Coapresta 2000, Sekisui, Japan). The blood that remained after the hematologic test was used for the serum biochemical analysis. The blood was centrifuged at 3,000 rpm for 10 minutes to collect the serum. Blood urea nitrogen (BUN), creatinine (Cr), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma glutamyl transpeptidase (GGT), total protein (TP), albumin (Alb) and albumin/ globulin ratio (A/G ratio), total bilirubin (T-bili), total cholesterol (T-Chol), triglycerides (TGs), phosphorus (P), glucose (Glu), and calcium (Ca) were measured with a blood chemical test analyzer (7180, Hitachi, Japan). Sodium (Na^+^), potassium (K^+^) and chloride (Cl^-^) were measured with an electrolyte analyzer (AVL9181, Roche, Germany).

Detailed visual examinations of entire organs were done for all animals after necropsy had been conducted. From the necropsied animals, injection sites were removed and fixed with 10% neutral buffered formalin (NBF). Fixed tissues underwent a general tissue processing process such as dehydration, paraffin embedding, and sectioning to make tissue slices, which was followed by hematoxylin and eosin (H&E) staining. Residual tissues were preserved with 10% NBF. Microscopic examinations were conducted for all injection sites on all test group rats, and histopathologic examinations were performed for all injection sites of the rats in all groups.

The data for weights, hematology and serum biochemistry were analyzed by using a statistical analysis system (SAS, version 9.3, SAS Institute Inc., U.S.A.). The continuous data are presented as means ± standard deviations. The test for equality of variance was done with the Bartlett test (*P* \< 0.05). If the variance data were normally distributed, the one way analysis of variance (ANOVA) was performed, followed by Dunnett\'s *t*-test for a post-hoc analysis. If those were not homogeneous, the Kruskall-Wallis test was done. A significance level of 0.05 for the two-sided test was considered statistically significant.

3. Results
==========

No deaths of either male or female SD rats were observed in either the control or the test (0.125, 0.25, and 0.5 mL/ animal) groups during the observation period (Table [2](#T002){ref-type="table"}). No abnormal clinical symptoms were observed in either male or female rats in either the control or test the groups during the observation period (Table [2](#T002){ref-type="table"}). No significant weight changes were noted for male and female SD rats in the test groups compared with those in the control group (Figs. [1](#F001){ref-type="fig"},[2](#F002){ref-type="fig"}).

Compared with control group, the test groups showed no significant differences in the hematological parameters, such as the RBC, HGB, HCT, MCV, MCH, MCHC, PLT, WBC, WBC differential count, and Reti count. No changes of parameters in serum biochemistry were observed in test group of male and female rats. No toxicological importance was found because the slight changes in the AST level in the female rat in the low dosage (0.125 mL/animal) group were sporadically observed with no dose dependence (AST in female group: 96.2 ± 23.7 U/L in the low dose (0.125 mL/animal) group *vs.* 69.0 ± 5.1 U/L in the control (0 mL/animal) group, 75.0 ± 8.8 U/L in the middle dose (0.25 mL/animal) group, and 84.6 ± 9.9 U/L in the high dose (0.5 mL/animal group); *P* \< 0.05). At necropsy, no macroscopic abnormalities were observed in either the control group or the test groups (Table [3](#T003){ref-type="table"}).

On the topical tolerance tests, no abnormal responses were noted at the injection sites on male and female SD rats in the test groups. In addition, histopathological tests showed that the observed changes, such as inflammatory cell infiltration in the low dose (0.125 mL/animal) group and inflammatory and focal macrophage cell infiltration in the high dose (0.5 mL/animal) group, appeared spontaneously and sporadically and showed no dose dependence (Table [4](#T004){ref-type="table"}).

4. Discussion
=============

Meridian fields (MFs) are areas of the body's functions that display similar properties for local disorders and are classified as wind, heat, fire, dry, damp, and cold MFs. The Heat MF is in wind, heat, dry, and fire MFs, and the Cold MF is in cold and damp MFs. The meridian body (MB) consists of the acupuncture points that have direct relevancy to a disease or disharmony, and it becomes sensitive and solidifies if the body is in a pathological state. The MB generates Qi and consumes lubrication (潤) to overcome the disorder. Body lubrication consists of nutrients, and Qi is energy. Both are used in the prevention and the treatment of the decrepitude and weak constitution. Diseases can be diagnosed and treated by using the principles of MFs and MB \[[@B001]\]. Aromatic and oil-based pharmacopuncture are two types of MFP that are applied to the MB or responsive points related to diseases. Aromatic pharmacopuncture is used to treat acute pain disorders caused by Qi stagnation and Blood stasis whereas oil-based pharmacopuncture is administrated to treat kinetic disorders caused by a deficiency of body lubrication \[[@B001]\].

CF (safflower) is the dried flowers of *Carthamus tinctorius* L., which belongs to the family Compositae. It contains carthamin, carthamidin, safftor yellow, and so on, and has the effect of activating blood to free the collateral vessels (活血通絡) and of dissipating stasis to relieve pain (散瘀止 痛). Safflower has been reported to extend blood vessels, to excite the uterus, to inhibit coagulation and platelet aggregation, and to reduce blood cholesterol. It is used to treat amenorrhea, traumatic wounds, chest and abdominal pain, and painful swelling due to blood stasis \[[@B011], [@B012]\]. The indications for the use of CF are similar to those for the use of CF, and it can be used to treat the elderly and severe deficiency of body lubrication \[[@B001]-[@B004], [@B013]\].

CC is extracted from DA, which is called Pilose Antler or Pilose Deer-horn (common name) and *Cornu cervi pantotrichum* (pharmaceutical name). DA uses the hairy, young horn of a male deer or stag, and the scientific name of DA is *Cervus nippon Temminck* or *Cervus elaphus* L. (family Cervidae). It is used to reinforce the vital function of the kidney and to strengthen the bones and muscles for the treatment of intolerance to cold, loss of strength, impotence, spontaneous seminal emission and other symptoms due to a deficiency of a vital function in chronic diseases \[[@B011], [@B012]\]. In addition, CC has been reported to restore dysfunction of the hypothalamic-pituitary-ovarian axis, associated with a significant increase of the serum estradiol level in ovariectomized rats, to increase growth, and to increase lipid metabolism and bone formation \[[@B014]-[@B016]\]. Therefore, CFC and WCFC, which are oil-based pharmacopuncture and mixtures of safflower and DA, can be applied to treat menopausal disease caused by a lack of female hormone, as well as kinetic disorders, degenerative osteoarthritis and spondylopathy with lubrication deficiency, which is caused by wind, fire, and dryness, such as frozen shoulder, tennis elbow, low back pain, pelvic pain, coccygodynia, compression fracture, and so on \[[@B001], [@B017], [@B018]\]. A small part of oil-based pharmacopunctures, such as CF, CFC, JSD, and CC, may be not absorbed and may be left in subcutaneous tissue or muscle because of the property of oil. These residues in the muscle or subcutaneous tissue can cause inflammation and produce side effects \[[@B007]-[@B009]\]. Thus, we hypothesize that WCFC can reduce the side effects of CFC that may occur in the clinic because WCFC emulsifies CFC in water and can be absorbed easily.

No mortalities or abnormal findings in body weights, clinical symptoms, and hematology and serum chemistry data were observed in this single-dose intramuscular-injection toxicology test. The histopathological test showed abnormal changes, such as inflammatory cell infiltration in the low dose (0.125 mL/animal) group and inflammatory and focal macrophage cell infiltration in the high dose (0.5 mL/animal) group (Table [4](#T004){ref-type="table"}). However, we speculate that those abnormalities have no toxicological meaning because they were spontaneous and sporadic and showed no dose dependence. Therefore, based on the results of this toxicity study, we conclude that WCFC is safe. However, additional safety studies or toxicological tests, such as 4-week, repeated toxicity tests and so on, as well as efficacy studies, are needed.

5. Conclusion
=============

The results of this single-dose toxicity study show that WCFC is safe because the lethal doses of WCFC in male and female SD rats were estimated to be higher than 0.5 mL/animal.

###### Grouping of animals

  Group                        Injection dose(mL/animal)   Number of animals   
  ---------------------------- --------------------------- ------------------- ---
  G1: Control group (Saline)   0.5                         5                   5
  G2: Low dose group (WCFC)    0.125                       5                   5
  G3: Mid dose group (WCFC)    0.25                        5                   5
  G4: High dose group (WCFC)   0.5                         5                   5

WCFC, water-soluble *Carthami-flos*and *Cervi cornu parvum*pharmacopuncture.

###### Summary of mortality and clinical signs

  --------------------------------------------------------------------------------------------------------------
  Sex          Group\              No. of\   Number of\       Mortality   Clinical\   0.5, 1, 2, 4,\   0 ─ 14\
               (Dose, mL/animal)   animals   deaths 0 ─\                  signs       6 hours\         Days\
                                             14 days after\                           (day 0) after\   after\
                                             dosing                                   dosing           dosing
  ------------ ------------------- --------- ---------------- ----------- ----------- ---------------- ---------
  Male         G1 (0)              5         0                0/5         NOA         5                5

  G2 (0.125)   5                   0         0/5              NOA         5           5                

  G3 (0.25)    5                   0         0/5              NOA         5           5                

  G4 (0.5)     5                   0         0/5              NOA         5           5                

  Female       G1 (0)              5         0                0/5         NOA         5                5

  G2 (0.125)   5                   0         0/5              NOA         5           5                

  G3 (0.25)    5                   0         0/5              NOA         5           5                

  G4 (0.5)     5                   0         0/5              NOA         5           5                
  --------------------------------------------------------------------------------------------------------------

NOA, no observable abnormality.

###### Summary of necropsy findings

  Sex                     Male   Female                                    
  ----------------------- ------ -------- ------ ----- ---- ------- ------ -----
  Group                   G1     G2       G3     G4    G1   G2      G3     G4
  Dose (mL/animal)        0      0.125    0.25   0.5   0    0.125   0.25   0.5
  No. of animals          5      5        5      5     5    5       5      5
  Unremarkable findings   5      5        5      5     5    5       5      5
  No. examined            5      5        5      5     5    5       5      5

External surfaces and all organs in the body cavity were unremarkable.

###### Summary of histopathological findings

                     Sex                   Male                  Female                                                                         
  ------------------ --------------------- ------ ------- ------ -------------- --------------------------------------- --- ---- ------- ------ -----
                     Group                 G1     G2      G3     G4                                                         G1   G2      G3     G4
                     Dose (mL/animal)      0      0.125   0.25   0.5                                                        0    0.125   0.25   0.5
                     No. of animals        5      5       5      5                                                          5    5       5      5
  Organ / Findings   Remarkable findings   0      0       0      0              Cell infiltration, inflammatory         ±   0    1       0      1
  Injection site     No. examined          5      5       5      5              Cell infiltration, macrophages, focal   ±   0    0       0      1
                                                                 No. examined                                           5   5    5       5      

Grade- ±, minimal.
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